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Introduction:Genetic and autoimmune risk factors contribute to the development of thrombotic thrombocytopenic
purpura (TTP) but triggers are needed to bring about acute disease.
The aim of the study was to investigate the association of neutrophil activation with acute TTP, to assess whether
neutrophil activation changes during plasma exchange therapy and to show if complement- and neutrophil
activation are parallel, characteristic processes in acute TTP.
Materials and Methods: Altogether 49 EDTA-plasma samples of 21 TTP patients with acute disease and 17 in
remission were investigated along with 20 healthy controls.
A stable complex of PMNE-proteinase-inhibitorwasmeasured by ELISA (Calbiochem,Merck-Millipore, Darmstadt,
Germany).
Results: Acute disease was associated with signiﬁcantly increased PMNE levels, the group medians were similarly
low in TTP patients in remission and in healthy controls. Increased PMNE levels were characteristic for
hematologically active and ADAMTS13 deﬁcient form of TTP. PMNE concentration inversely correlated to disease
activity markers platelet count (r = −0.349, p = 0.032) and hemoglobin levels (p = −0.382 p = 0.018).
Achievement of remission was associatedwith signiﬁcant reduction of plasma PMNE levels (p= 0.031,Wilcoxon
test). There was positive correlation between PMNE levels and complement activation markers C3a and Bb.
Conclusions:We report increased PMNE levels in acute TTP and showed its association to activity markers of acute
TTP and complement activation. Effective treatment of an acute TTP episode resulted inmarked decrease in PMNE
levels. Our data support and extend previous observations that neutrophil extracellular traps may be released in
acute TTP and potentially contribute to the pathophysiology of this disease.© 2014 Elsevier Ltd. All rights reserved.Introduction
Various etiological factors represent increased risk for the develop-
ment of thrombotic thrombocytopenic purpura (TTP), a life-threatening
disorder. Characteristic clinical features of TTP are microangiopathic
hemolytic anemia, thrombocytopenia and various involvements of
other organs, for example the kidneys and the nervous system [1,2]. In
most cases development of functional inhibitors (autoantibodies) against
the von Willebrand factor (VWF) cleaving protease (A Disintegrin and
Metalloproteinase with ThromboSpondin-1 like motifs-13, ADAMTS13)
predispose to disease. Inherited variations of ADAMTS13may also confer
increased risk of TTP development, whereas a minor part of TTP patients
presents with non-ADAMTS13 deﬁcient disease form [3]. Severe
deﬁciency of ADAMTS13 leads to the increased presence of unusuallyst. 4. Tel.:+36 1 3251379,+36
ghts reserved.large multimers of VWF that promote the formation of platelet rich
thrombi in the capillaries and small vessels leading to tissue ischemia
and organ failure [4].
However, ADAMTS13 deﬁcient patients may remain asymptomatic
for several years [5,6]. Furthermore, several patients may go into
sustained clinical remission despite deﬁcient ADAMTS13 activity [7,8].
In addition, although patients with acute TTP often present without
acute disease in history, in the majority of TTP patients infections or
pregnancy precede the acute diseaseﬂare [9]. Thesewell-known clinical
observations collectively indicate that multiple hits may be necessary
for the development of clinically active TTP, and ADAMTS13 deﬁciency,
even though it is probably the most important predisposing risk factor,
it is alone not sufﬁcient to cause acute TTP.
Previously our group reported on the presence of complement acti-
vation in patients with acute TTP [10] an observation recently con-
ﬁrmed in an independent cohort [11]. Our data indicated that
activation of the classical/lectin and alternative pathways that lead to
the activation of the terminal pathway was present in TTP. It is known
617B. Mikes et al. / Thrombosis Research 133 (2014) 616–621that activation of the complement systemand of neutrophil granulocytes
is characteristic for most infections and also in pregnancy, especially if
complicated with preeclapmsia and/or fetal growth restriction [12,13].
Therefore, we hypothesized that neutrophil activation may associate
with acute, ADAMTS13-deﬁcient TTP and potentially contribute to the
development of clinically active thrombotic microangiopathy.
Supporting this hypothesis were results of a recent study showing in-
creased circulating DNA and myeloperoxidase levels in patients suffer-
ing from thrombotic microangiopathies (TMAs) [14]. Hence, the aim of
the current study was to formally investigate the association of neutro-
phil activation with acute TTP, to assess whether neutrophil activation
changes during plasma exchange therapy and to show if complement-
and neutrophil activation are parallel, characteristic processes in acute
TTP.
Materials and Methods
Patients and Plasma Samples
Thirty-eight patients with TTP were enrolled in this single-research
laboratory based investigation providing diagnostic services (ADAMTS13
and complement measurements) since August, 2007 for patients
suspected to have HUS or TTP in Hungary. The patient enrolment forTable 1
Clinical and laboratory data of the 38 patients with thrombotic thrombocytopenic purpura.
Registry
code
Age at
blood
sampling
(years)
Sex Acute/
Remission
ADAMTS13 activity
of patient's sample
(FRETS-VWF73);
reference
range 67-147%
ADAMTS13 activity
of mixed sample
(patient's plasma
with pooled plasma 1:1)
(FRETS-VWF73); reference
range N50% of the daily
control sample
HUN1 26 F Acute 0 0
HUN15 55 M Acute 0 0
HUN23 38 M Acute 0 30
HUN43 62 F Acute 0 26
HUN50 17 F Acute 0 9
HUN56 44 F Acute 0 0
HUN62 35 F Acute 0 11
HUN68 43 M Acute 5 6
HUN72 13 F Acute 0 0
HUN76 57 F Acute 0 23
HUN85 49 F Acute 0 0
HUN86 42 F Acute 0 5
HUN96 22 F Acute 5 23
HUN97 51 F Acute 0 15
HUN112 71 F Acute 0 ND
HUN113 25 F Acute 0 0
HUN123 45 F Acute 0 18
HUN126 36 M Acute 0 0
HUN127 30 F Acute 0 0
HUN131 44 F Acute 0 0
HUN134 44 F Acute 0 0
HUN3 40 M Remission 0 30
HUN28 36 F Remission 68 61
HUN31 33 F Remission 0 29
HUN35 37 F Remission 0 0
HUN53 51 F Remission 0 18
HUN54 56 F Remission 104 ND
HUN58 46 F Remission 74 ND
HUN59 44 F Remission 112 ND
HUN65 35 F Remission 0 44
HUN70 47 F Remission 97 33
HUN78 47 F Remission 0 0
HUN80 31 M Remission 109 87
HUN81 21 F Remission 7 20
HUN89 33 M Remission 0 23
HUN100 40 F Remission 109 75
HUN101 61 F Remission 79 65
HUN115 51 F Remission 19 ND
NA: not available; ND: not done.this study was closed in January, 2011. The criteria used to guide patient
stratiﬁcation, diagnosis and sample selection have been described in de-
tails [10]. Brieﬂy, diagnosis of TTP was based on one or more episodes of
Coombs-negative microangiopathic hemolytic anemia with thrombocy-
topenia deﬁned as serum lactate dehydrogenase (LDH) N450 U/L;
fragmented erythrocytes in the peripheral blood smear and platelet
count b150G/L; only patientswith severely decreased ADAMTS13 activ-
ity levels (b5%), or history of it, were included in this study. Patientswith
acute oligo-anuric renal failure were excluded from the study. Hemato-
logical remission (HR) was determined when platelet counts were
N150 G/L on two consecutive days without any sign of hemolysis even
if there were any neurological, renal or other residual clinical symptoms,
whereas complete remission (CR) was established when, platelet count
remained above the lower limit continuously for at least 1 month.
Table 1 shows clinical and laboratory data of the cohort who had
available plasma samples for the current study. Using samples of this
TTP cohort we measured plasma polymorphonuclear cell elastase
(PMNE) levels during acute disease ﬂare, in remission, and for compar-
ison in controls. Samples of 38 TTP patients have been investigated.
Twenty-one patients with acute disease (mean age 40 years, SD 15, 17
women), 17 TTP patients in remission (mean age 42 years, SD 10, 14
women) and 20 healthy age- and sex matched controls (mean age
35 years, SD 17, 15 women) were enrolled. Eight patients with acuteHemoglobin;
reference ranges,
females 123–153 g/L,
males 140–175 g/L
Platelets;
reference range
150–400 G/L
White Blood
Cells; reference
range 4–10 G/L
Absolute
neutrophil
count;
reference
range 2.12-
7.5 G/L
PMN elastase
proteinase
inhibitor
complex
(ng/mL)
80 33 31,50 25,51 3,10
108 22 12,06 10,61 0,82
91 45 6,40 3,21 0,63
72 28 6,53 5,68 0,53
76 17 11,20 7,71 2,72
83 44 6,81 4,44 0,57
81 18 11,63 9,13 1,76
64 9 6,30 4,38 1,15
72 84 10,80 8,48 5,61
85 30 7,11 5,02 2,46
85 31 11,34 10,26 0,62
78 12 5,37 3,17 0,91
53 23 7,16 4,48 1,59
126 43 12,19 5,88 1,01
103 44 3,69 2,14 0,72
109 22 10,45 6,21 4,19
97 76 32,82 12,61 2,92
69 43 6,79 3,63 1,81
75 12 8,93 8,09 1,90
126 48 11,12 7,77 0,49
80 19 7,99 5,84 1,08
154 244 10,51 8,20 0,54
NA 213 NA NA 0,88
153 275 6,82 3,41 0,47
123 272 18,70 10,28 0,86
135 174 6,85 4,67 0,57
140 115 6,11 3,92 12,00
136 158 5,71 3,31 0,49
119 184 5,85 3,35 0,81
150 388 15,70 11,41 4,22
NA 213 NA NA 0,73
134 210 7,94 4,64 0,55
169 246 9,68 4,84 1,13
124 308 22,93 19,42 1,05
156 260 5,37 2,84 0,54
144 213 5,88 3,65 0,47
123 196 6,89 5,49 0,58
149 433 12,99 10,05 0,42
Fig. 1.Neutrophil elastase (PMNE) ismarker of acute TTP. (A) Plasma neutrophil-elastase-
alpha1-proteinase inhibitor complex (Calbiochem, Merck-Millipore, Darmstadt,
Germany) was measured in EDTA-plasma samples of healthy controls, TTP patients in
complete remission) and in TTP patients with acute disease ﬂare. Horizontal lines indicate
group median, P values were obtained by Mann–Whitney test.
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istry codes 1, 15, 62, 68, 86, 127) had plasma samples taken in hemato-
logical remission, after ﬁnishing the PEX series. Five of them (registry
codes 68, 86, 126, 127, 131) had plasma samples taken during during
PEX series, before reaching hematological remission. Thus, altogether
49 EDTA-plasma samples were used for PMNE determination.
Blood samples (EDTA-anticoagulated plasma and sodium-citrate
anticoagulated plasma) were taken by antecubital venipuncture or
from central catheter, cells and supernatant separated by centrifugation
and shipped in cooled packages (−20 degrees of Celsius) to the
Research Laboratory, where aliquots were made and stored in
ultrafreezers on b−70 degrees of Celsius until determinations.
From each subject, informed consent was obtained and the study
was approved by the institutional Ethics Committee on human research.
Determination of Plasma Polymorphonuclear Cell Elastase (PMNE) Levels
and other Laboratory Parameters
A stable complex of PMNE-alpha1-proteinase-inhibitor was mea-
sured by sandwich type ELISA (QIA96, Calbiochem, Merck-Millipore,
Darmstadt, Germany), according to the instructions given by the
manufacturer.
The ﬂuorigenic substrate, FRETS-VWF73, was applied for the deter-
mination of ADAMTS13 enzyme activity as described [15]. Brieﬂy,
citrated plasma was diluted 1:20 in assay buffer (5 mmol/l Bis-Tris,
25 mmol/L CaCl2, 0.005% Tween 20, pH 6.0) and mixed with 5 μmol/L
FRETS-VWF73 substrate solution (20 μl each), in white 384-well plates.
Fluorescence was measured at 37 °C every 2 minutes for 1 hour in Cha-
meleon microplate reader (Hidex, Turku, Finland) equipped with a
340 nm excitation and a 460 nm emission ﬁlter. The reaction rate was
calculated by linear regression analysis of ﬂuorescence over time. A
two-fold dilution series of normal human plasma (mixed from citrated
plasma samples of 10 healthy blood donors) was applied as standard
curve, 100% ADAMTS13 activity was set at the reaction rate observed
in the 1:20 diluted sample. The intra-assay variation coefﬁcient was
b5%, the inter-assay CV% was 6-9% (measured at 60 and 100% activity
levels). The presence of anti-ADAMTS13 inhibitors was determined by
mixing 1 part of the patient’s sample with 1 part of normal pooled plas-
ma, incubation at 37 degrees of Celsius for 2 hours, andmeasurement of
ADAMTS13 activity of the sample. The presence of ADAMTS13 inhibi-
tors was considered if the patient’s original sample had b7% activity,
and that of the mixed sample was b50%.
Levels of complement activation products C3a (MicroVue C3a des-
arg EIA A031, mean of healthy controls 129.6 ng/mL), Bb (MicroVue
Bb EIA, A027, mean + 2SD range 0.49-1.42 μg/mL) were determined
with commercial Kits (Quidel, San Diego, California, USA) according to
the manufacturer’s instructions in EDTA plasma samples.
Statistical Analysis
The continuous variables reported in this study showed skewed dis-
tribution and according to results of Shapiro-Willk’s test deviated from
the normal distribution. Therefore, for descriptive purposes the values
of each measurement are given as median and 25th-75th percentile,
or as numbers (percent) and non-parametric tests were used for
group comparisons; continuous variables between two groups were
compared with Mann–Whitney U test, for three or more groups with
the Kruskal-Wallis ANOVA by ranks test, and for repeated measures
with the Friedman test. Dunn’s post-test was used for group compari-
sons after analysis of variance. Spearman’s correlation coefﬁcients
were calculated by non-parametric method. Statistical analyses were
carried out using STATISTICA 7.0 (StatSoft Inc., Tulsa, OK, USA) and
GraphPad Prism 4.03 (GraphPad Softwares Inc., CA, USA) softwares.
Two tailed p values were calculated and the signiﬁcance level was put
at a value of p b 0.050.Results
Acute TTP is Associated with Increased PMNE Levels
Table 1 shows clinical and laboratory data of the cohort. All of the pa-
tients in acute diseaseﬂare (n=21)were ADAMTS13 deﬁcient (activity
b5%) and positive for anti-ADAMTS13 inhibitors. Samples for PMNE
determinations were taken before the initiation of a series of plasma
exchange sessions in 13 patients, whereas for the remaining 8 cases
sampling was done during the PEX series. Seventeen patients were
enrolled in complete remission, 8 of them were ADAMTS13 deﬁcient
(1 patient had 7% activity and was positive for inhibitor), 8 patients
had ADAMTS13 activity within the reference range, and 1 patient had
moderately decreased level. Increased absolute neutrophil counts
were not associated with acute TTP (Table 1), the median (IQR) values
for acute patients was 6.0 G/L (4.4-9.7) whereas for patients in remission
4.7 G/L (3.4-9.1; p = 0.223).
Acute disease was associated with signiﬁcantly increased PMNE
levels, whereas the group medians were similarly low in TTP patients
in remission and in healthy controls (Fig. 1). Patients in remission
with (0.54 ng/mL, 0.53-0.86) or without (0.73 ng/mL, 0.48-1.00)
ADAMTS13 deﬁciency had similar PMNE levels (p = 0.680). Further-
more, increased PMNE levels and deﬁcient ADAMTS13 activity together
characterized hematologically active disease (plt b 150 G/L, Fig. 2, panel
A). Note, that there were no patients in our cohort with non-deﬁcient
ADAMTS13 activity and decreased platelet counts. In line with this ob-
servation there was a signiﬁcant association between amounts of func-
tional ADAMTS13 inhibitors (as assessed by measuring the ADAMTS13
activity of the mixed patient/normal plasma samples) and PMNE levels
(Fig. 2, panel B). There was no signiﬁcant correlation between
ADAMTS13 activity (measured in patient’s own samples) and PMNE
levels (data not shown). Similarly, no association between PMNE levels
and neutrophil counts was observed (r =−0.381, p = 0.064, data not
shown) and neutrophil counts were similar in acute and remission
groups, excluding the possibility of themere reﬂection of higher neutro-
phil counts by increased PMNE levels. Finally, we investigated changes
of PMNE levels during therapy. There were 5 patients with available
samples before the initiation of PEX series, and during that. In 4 out of
the 5 patients, PMNE levels decreased by 40-60%, whereas in one pa-
tient it increased by 187%. Similarly, we investigated PMNE levels in
samples of 6 patients (4 women) with available samples collected on
the day of admission, before the initiation of PEX series, and also in
hematological remission at least 1 week after the last session of the
PEX series. As shown in Fig. 3, achievement of remission was associated
with signiﬁcant reduction of circulating plasma PMNE levels in patients
with TTP.
Fig. 2. (A)Elevated PMNE level togetherwith deﬁcientADAMTS13activity is characteristic
for hematologically active TTP. Analysis of 46 samples of patients with hematologically ac-
tive TTP (platelet below 150 G/L) or in hematological remission (platelet above 150 G/L),
as stratiﬁed by the presence of ADAMTS13 deﬁciency (activity b5%). P valueswere obtain-
ed by Mann–Whitney test. (B) Correlation between functional ADAMTS13 inhibitor and
PMNE concentrations. Inhibitors against ADAMTS13 were assessed in 33 samples of pa-
tients with TTP bymixing studies as described in theMaterials andMethods section. Sam-
ples taken in acute TTP aremarkedwith closed symbols, whereas those taken in remission
are marked with open symbols. Horizontal lines indicate group median, correlation
coefﬁcient with p value was calculated by Spearman’s non-parametric method: pooled
analysis r =−0.428, p= 0.013; acute TTP: r =−0,547, p= 0.012; TTP in remission:
r = 0.171, p = 0.577).
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Activation Products
Next, correlations between TTP activity markers and PMNE levels
were analyzed. The amount of PMNE showed inverse correlation toFig. 3. Changes of plasma neutrophil elastase (PMNE) levels during treatment of acute
disease ﬂare in TTP. Comparison of PMNE concentrations in plasma from 6 patients
(4 women) with TTP collected at the presentation with acute disease (acute TTP) or
in hematological remission (HR). P value was obtained by Wilcoxon test.platelet count and hemoglobin levels in the whole TTP cohort (Fig. 4,
panel A and B). Fourteen patients with acute TTP received packed red
blood cells before sampling for PMNE determinations. The signiﬁcant
inverse association is present between PMNE and hemoglobin levels
if these subjects are excluded form the analysis presented on Fig. 4B
(r = −0.427, p = 0.037). Result of stratiﬁed correlation analysis
(although underpowered due to low patient numbers) is presented
in legend for Fig. 4.
In a subset of these patients levels of complement factors and ac-
tivation products have beenmeasured previously. Increased levels of
C3a and terminal pathway complex (TCC) were observed in acute
TTP [10]. Therefore, we analyzed if any of the complement factors
or activation products show association with activity markers of
neutrophils. As shown in Fig. 5, concentrations of the activity marker
of the alternative pathway convertase’s enzymatic component Factor B
(Bb, r = 0.392, p = 0.015) and anaphylatoxin C3a (r = 0.367, p =
0.024) showed signiﬁcant, positive correlation to PMNE levels. No
other signiﬁcant correlation between complement components (C3,
Factors B, H, I, r = −0.171, -0.287, 0.015, 0.255, respectively, all p
N 0.05) or activation products (C1r-C1s-C1-inhibitor, C4d, C3bBbP,
TCC, 0.025, 0.058, 0.017, 0.199, respectively, all p N 0.05) and PMNE
concentration was observed.Fig. 4. Association of plasma neutrophil elastase (PMNE) levels with disease activity
markers in TTP. Correlation coefﬁcients and p values between plasma PMNE levels
and platelet counts (A) or hemoglobin levels (B) were calculated by the Spearman
non-parametric method (Panel A, pooled analysis: r = −0.483, p = 0.006; acute
TTP: -0.521, p = 0.015; TTP in remission: r = −0.086, p = 0.743; Panel B, pooled
analysis: r =−0.382, p = 0.018, acute TTP: -0.353, p = 0.116; TTP in remission: r =
−0.257, p= 0.318). Samples taken in acute TTP aremarkedwith closed symbols, where-
as those taken in remission are marked with open symbols.
Fig. 5. Association of plasma neutrophil elastase (PMNE) levels with complement ac-
tivation products in TTP. Correlation coefﬁcients and p values between plasma PMNE
levels and activated factor B (Bb) (panel A) or anaphylatoxin C3a (panel B) levels
were calculated by the Spearman non-parametric method (Panel A r = 0.392, p = 0.015;
Panel B r= 0.367, p= 0.024). Samples taken in acute TTP aremarkedwith closed symbols,
whereas those taken in remission are marked with open symbols.
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Here we report on two novel ﬁndings. First, in a well-characterized,
homogenous ADAMTS13-deﬁcient, inhibitor positive cohort of TTP pa-
tients elevated neutrophil activation marker, PMNE, was shown to be
increased in acute disease ﬂare. PMNE levels were directly related to
disease activity markers hemoglobin and platelet count, and correlated
with the amounts of functional ADAMTS13 inhibitor. Second, according
to the presented data, neutrophil- and complement activation are
present parallel in acute TTP and correlate to each other.
The potential link between thrombotic microangiopathy and neu-
trophils was ﬁrst studied and characterized in E. coli caused typical
HUS. Increased initial neutrophil count was shown to be predictive for
bad outcome in D + HUS [16]. Further, neutrophil markers (elastase,
myeloperoxidase and IL-8) were elevated and linked to endothelial
cell damage and thrombin activity in typical HUS [17]. Similar observa-
tions have been reported for a few diarrhea negative HUS patients [18].
Recently, elevated myeloperoxidase and circulating DNA levels were
shown in patients with various forms of TMA (ADAMTS13 deﬁcient
TTP, D + HUS, tumor-associated TMA and TMA of with unknown etiol-
ogy). Increased plasma DNA and MPO levels together with ADAMTS13
deﬁciency characterized the acute disease state in patients with
acquired TTP. Authors concluded that circulating DNA and histones in
patients with TMA could have originated from neutrophil extracellular
traps (NETs) [14].Neutrophils release processed chromatin termed neutrophil extra-
cellular traps (NETs) to trap and kill pathogens [19]. NETs are implicated
in immune defense [20], sepsis [21] and autoimmunity [22]. NET is
formed by a DNA-histones scaffold that contains granule proteins such
as elastase and myeloperoxidase, as well as antimicrobial peptides
[23]. Results obtained in PMNE knock-out mice showed that these ani-
mals do not form NETs in a pulmonary model of bacterial infection
[24]. These and other studies [24] collectively demonstrated that
PMNE is essential for the initiation of NET formation and is externalized
together with NETs after stimulation of neutrophils. Therefore, based on
our results we conclude that the increased PMNE levels in acute TTP
may originate from neutrophils in a process of cell activation and NET
release. Our observations independently conﬁrm the results of Fuchs
et al., regarding the contribution of neutrophil activation to the patho-
genesis of acute TMAs, and its correlation to disease activity.
Activation of neutrophils, as assessed by a speciﬁc biomarker,
elastase, is characteristic for hematologically active TTP. Patients
with N150 G/L platelet counts and deﬁcient ADAMTS13 activity had
similar mean PMNE level to those in remission without ADAMTS13
deﬁciency (Fig. 2), and also similar to healthy controls (Fig. 1). Fur-
thermore, treatment of acute TTP by a series of PEX sessions resulted
decrease of PMNE levels in the majority of patients during PEX,
whereas the reduction was signiﬁcant (Fig. 3) after reaching of he-
matological remission. These results support the multiple hit con-
cept in the pathogenesis of TMAs, speciﬁcally, TTP. Acute TMA
ﬂares often follow infections or precipitate during or after pregnancy
and neutrophil activation is known to be increased in these clinical
states [9]. In genetically (rare or common variants in ADAMTS13) or
immunologically (ADAMTS13 inhibitors) predisposed individuals,
activation of neutrophils and release of NETs may precipitate acute
TTP by multiple mechanisms. As shown in mouse model, DNA and
histones stimulate thrombosis and promote cytotoxicity [25–27]. In
addition, reactive oxygen species released by activated neutrophils
have prothrombotic effect, mediated in part by inhibition of VWF
cleavage by ADAMTS13 [28]. Finally, leukocyte proteases including
elastase cleave von Willebrand factor at or near the ADAMTS13
cleavage site andmay therefore participate in the proteolytic regulation
of VWF [29].
Furthermore, NETsmay activate complement leading to C3b deposi-
tion to NET components and generation of C5a [30]. Previously we [10]
and others [11] documented the activation of the classical/lectin, the al-
ternative and the terminal pathways of complement in TTP. Our current
results indicate the association between PMNE and C3 activation (C3a),
and the presence of NETsmay be a potential link between these factors.
The presence of correlation between PMNE and Bb levels point to the
initiation of alternative ampliﬁcation loop extending complement acti-
vation. Complement activation attracts and activates neutrophils
[31,32], and in turn may exacerbate NET release, initiating a positive
feed-back loop. These observations are in line with the recent report
on the association among circulating nucleosomes, activated neutro-
phils (as indicated by increased neutrophil elastase-α1-antitrypsin
complexes), and presence of deep vein thrombosis [33]. Taken together,
evolutionarily conserved innate mechanisms acting in concert may
stimulate thrombosis, endothelial damage [34,35] and contribute to
the precipitation of acute TTP.
Currently PMNE measurement is possible only by manual
immuno- and enzymatic assays, therefore this restricted availability
and relatively high costs limit its potential clinical application. However,
if these observations can be repeated in independent cohortsmarkers of
neutrophil activation may potentially help to stratify patients between
therapeutic modalities and to guide time and frequency of plasma
exchange treatment.
We acknowledge potential limitations of our study. TTP is a rare
disorder, and we were unable to enrol more patients in a reasonable
short time-frameallowing the correct analysis of elastase andneutrophil
activation. Therefore, due to the low number of patients some of the
621B. Mikes et al. / Thrombosis Research 133 (2014) 616–621analysis presented here are underpowered, there is a possibility for the
presence of false negative or false positive conclusions in the results
(especially for the correlation analysis), and therefore some of the con-
clusions have to be taken as preliminary, until independent conﬁrma-
tion is published.
In conclusion, we report the association of increased plasma neu-
trophil elastase levels with acute TTP. Increased PMNE levels were
directly related to hematologically active TTP, to functional
ADAMTS13 inhibitors, disease activity markers of acute TTP (hemoglo-
bin concentrations and platelet counts) and complement activation
markers of the alternative pathway. Effective treatment of an acute
TTP episode resulted in marked decrease in PMNE levels. Our data
lend credence to the hypothesis that neutrophil extracellular traps
may be released in acute TTP and may potentially contribute to the
pathophysiology of this disease. We identiﬁed complement activation
products associated with high PMNE levels indicating for the presence
of a potential positive feed-back loop between innate mechanisms
behind the precipitation of acute TTP.
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